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Abstract
Background Interleukin-25 (IL-25) is a potent activator
of type-2 immune responses. Mucosal inflammation in
ulcerative colitis is driven by type-2 cytokines. We have
previously shown that a neutralizing anti-IL-25 antibody
abrogated airways hyperreactivity in an experimental
model of lung allergy. Therefore, we asked whether
blocking IL-25 via neutralizing antibodies against the
ligand or its receptor IL-17BR could protect against
inflammation in an oxazolone-induced mouse model of
colitis.
Methods Neutralizing antibodies to IL-25 or IL-17BR
were administered to mice with oxazolone-induced colitis,
a model of ulcerative colitis. The disease onset was eval-
uated by weight loss and degree of colon ulceration.
Also, lamina propria and mesenteric lymph node (MLN)
infiltrates were assessed for mucosal inflammation and
cultured in vitro to determine cytokine production.
Results We found that in oxazolone colitis IL-25 pro-
duction derives from intestinal epithelial cells and that
IL-17BR? IL-13-producing natural killer T (NKT) cells
and nuocytes drive the intestinal inflammation. Blocking
IL-25 signalling considerably improved the clinical aspects
of the disease, including weight loss and colon ulceration,
and resulted in fewer nuocytes and NKT cells infiltrating
the mucosa. The improved pathology correlated with a
decrease in IL-13 production by lamina propria cells, a
decrease in the production of other type-2 cytokines by
MLN cells, and a decrease in blood eosinophilia and IgE.
Conclusion IL-25 plays a pro-inflammatory role in the
oxazolone colitis model, and neutralizing antibodies to
IL-25 or IL-17BR can slow the ongoing inflammation in
this disease. Because this model mimics aspects of human
ulcerative colitis, these antibodies may represent potential
therapeutics for reducing gut inflammation in patients.
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Introduction
Inflammatory bowel diseases (IBDs), such as Crohn’s
disease (CD) and ulcerative colitis (UC), are inflammatory
disorders of the digestive tract that occur due to a dys-
functional immune response to usually harmless com-
mensal bacteria [1]. These immune responses have been
broadly divided into Th1, Th2, or Th17-type responses
depending on the T-helper cell type driving the response
and the respective cytokine profile. Generally, CD is
characterized by a transmural, discontinuous inflammation
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that is associated with a type-1 response mainly driven by
interleukin (IL)-12 and interferon (IFN)-c [2, 3], while UC
involves the superficial mucosal and submucosal layers of
the colon and is driven by type-2 cytokines, such as IL-4,
IL-5, and IL-13 [1, 4]. IL-4 and IL-5 expressions were
previously quantified in intestinal tissue and correlated
with the clinical and histological severity of colitis in UC
patients [5], and IL-13, which was also found to be up-
regulated in UC, was linked to an impaired epithelial
barrier function in the gut [6]. In mice, mucosal inflam-
mation can be induced by the administration of dextran
sulfate sodium (DSS) or haptenating agents, such as 2,4,6-
trinitrobenzenesulfonic acid (TNBS) and oxazolone [7].
These agents result in very different types of inflammation
in the gut, with the first two skewing towards a type-1
phenotype [8, 9], whereas the oxazolone model shows a
clear type-2 inflammatory response [10–12].
IL-25 was originally found by sequence homology to
other IL-17 family members [13], although unlike the other
IL-17 cytokines, IL-25 function has been associated with
type-2-like inflammation [14, 15]. Expression of IL-25 has
been reported in several tissues, including lung, stomach,
small intestine, and colon [14] and in cell types such as
macrophages and epithelial cells in the gut [14, 16], Th2
cells [14], mast cells [17], and natural killer T (NKT) cells
[18]. IL-25 mediates its biological effects through the
receptor IL-17BR, which forms a receptor complex with
IL-17RA, both being essential for IL-25 effector functions
in the intestine [19]. IL-25-induced inflammation is typi-
cally characterized by elevated levels of type-2 cytokines
which lead to pathological changes in the lungs and
digestive tract, such as elevated serum IgE and IgG1,
increased mucus secretion, and epithelial cell hyperplasia
[20–22]. A key role for IL-25 in driving lung inflammation
during allergic asthma has been widely reported [23–25],
with its expression up-regulated in the nasal lavage fluids
of asthmatic patients [26]. Moreover, in a mouse model of
lung inflammation, we have shown that blocking IL-25
with a neutralizing anti-IL-25 antibody completely abro-
gated airways hyperreactivity (AHR) [23]. In another
mucosal context, the intestine, IL-25 has been described to
play a role in the protection against helminth infection [27]
by inducing a strong type-2 innate inflammation which is
dependent upon the activation of IL-17BR? nuocytes and
their production of IL-13 [28]. In gut inflammation, such as
colitis, an anti-inflammatory role has been attributed to IL-
25 in type-1 models of this disease by two separate groups
[16, 29], but an exact mechanism of how IL-25 acts to
prevent gut inflammation in these models has not been
described in full, although IL-25 was associated with the
regulation of IL-12 production and induction of alterna-
tively activated macrophages with anti-inflammatory
properties [30]. In another model, severe intestinal
inflammation following chronic Trichuris muris infection
was shown to develop in mice that were IL-25-deficient,
correlating with a heightened expression of Th1/Th17
cytokines, IFN-c, and IL-17 [31]. Despite these findings,
there is so far no record of an anti-inflammatory role for IL-
25 in type-2-skewed colitic inflammation. Type-2 gut
inflammation is not driven by IL-12 and IFN-c, but is
thought to be caused by elevated levels of IL-4, IL-5, and
IL-13 [32] and studies have shown a delay in the onset of
colitis when IL-4 is blocked by a neutralizing anti-IL-4
antibody [11]. Similarly, when IL-13 downstream effector
functions are blocked, via the elimination of NKT cells or
by using an IL-13 receptor a2-fusion protein, the devel-
opment of colitis is prevented [10], whereas antibodies
against IL-12 severely aggravate the disease [11]. In two
recent studies, another type-2-associated cytokine, IL-33,
has been associated with UC [33, 34], pointing to different
inflammatory outcomes depending on which type of IBD is
being studied. Therefore, because IL-25 is known for
driving IL-13 production by IL17BR? cells [28, 35] and
for inducing type-2 inflammation in the lung and gut, we
hypothesized that IL-25 might have a pro-inflammatory
role in the type-2 model of colitis. We sought to investigate
the role of IL-25 in type-2 gut inflammation using neu-
tralizing antibodies against the cytokine and the IL-17B
receptor. We demonstrate that IL-25 plays a critical role in
mediating intestinal type-2 inflammation in oxazolone
colitis and that, in contrast to the DSS and TNBS type-1
models, it acts as a pro-inflammatory cytokine. Our data
suggest that IL-25 is essential for type-2 cytokine pro-
duction by mesenteric lymph node (MLN) cells, as well as
being essential for IL-13 production by leukocytes in the
intestinal mucosa; this result supports previous findings in
helminth infection and in lung inflammation [23, 27]. In
addition, we also found that blocking IL-25 signalling
decreased the number of inflammatory cell types such as
nuocytes and NKT cells in the lamina propria.
Materials and methods
Animals
Wild-type female BALB/c mice were obtained from
Charles River Laboratories (Margate, UK). All mice were
maintained in a specific pathogen-free environment.
Experiments were conducted under license from the United
Kingdom Home Office.
Induction of colitis and antibody treatment
Oxazolone (4-ethoxymethylene-2-phenyl-2-oxazoline-5-
one) was obtained from Sigma-Aldrich (St. Louis, MO,
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USA). Induced gut inflammation was performed according
to a recently described method of sensitization and chal-
lenge [10]. To pre-sensitize mice, a 2 9 2 cm field of the
abdominal skin was shaved and 150 ll of a 4 % (w/v)
solution of oxazolone (OXA) in 100 % ethanol (EtOH) was
applied. Seven days after pre-sensitization mice were
challenged intrarectally with 150 ll of 3 % OXA in 50 %
EtOH, under anesthesia with isoflurane. Control mice
received EtOH only. Neutralization of IL-25 signalling in
vivo was performed at 500 lg/mouse with monoclonal
antibodies (mAbs) against IL-25 (Clone 2c3.1 or DDG91)
[23] or IL17BR (Clone D9.2), made in house [28]. The
isotype control used in this study was anti-c-myc mouse
IgG1 (Clone 9e10.2). All antibodies were tested for
endotoxin presence and used at concentrations lower than
0.01 EU/mg of antibody. Clinical symptoms were scored
blind on day 1 and day 2 after intrarectal challenge and
assigned clinical scores according to Table 1.
Histological assessment of colitis
Colons were collected on day 2 post-intrarectal instillation
and fixed in formalin (10 % formalin in 0.9 % saline
solution). After paraffin embedding, 5-lm sections were
cut and stained with hematoxylin and eosin (AML Labs,
Baltimore, MD, USA). Stained sections were examined
blind for evidence of colitis.
Cell isolation and culture
MLN cells were isolated on day 2 after colitis induction by
dispersing the tissue and filtering the cell suspension through a
70-lm cell strainer. Cells were cultured in RPMI 1640 sup-
plemented with 10 % fetal bovine serum (FBS), 1 % peni-
cillin and streptomycin, and 0.1 mM 2-mercaptoethanol.
Lamina propria (LP) cells were isolated on day 2 from colonic
tissue as previously described [36]. In brief, colon epithelial
cells were isolated by the incubation of colon strips
in RPMI/5 mM ethylediamine tetraacetic acid (EDTA). Epi-
thelial cells were used for RNA extraction. Lamina pro-
pria (LP) cells were released by digestion of the tissue
with RPMI/4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) supplemented with 60 lg/ml DNaseI (Sigma),
and 400 ng/ml of Liberase (Roche Applied Science, Burgess
Hill, UK). Total LP cells were collected at this point for flow
cytometric analysis. To isolate lymphocytes, cells were then
collected by centrifugation in a discontinuous (40–100 %)
Percoll gradient (GE Healthcare, Little Chalfont, UK).
Finally, the lymphocyte-enriched population was further
purified by negative selection using a CD45?-cell isolation kit
(Miltenyi Biotec, Surrey, UK). For the cell cultures, lym-
phocytes were stimulated in vitro for 48 h with plate-bound
anti-CD3 (1 lg/ml; BD Biosciences, Oxford, UK) and soluble
anti-CD28 (1 lg/ml; BD Biosciences).
Isolation of nuocytes was performed by magnetic
depletion of MLN cells and/or splenocytes using biotinyl-
ated antibodies against CD3 (145-2C11), CD19 (eBio1D3),
FceRI (MAR-1), and CD11b (M1/70). Negative selection
was performed using magnetic cell sorting with streptavi-
din-conjugated beads (Dynabeads M-280; Invitrogen Dy-
nal, Life Technologies Ltd, Paisley, UK). Cells were then
incubated with IL-25 (R&D systems, Abington, UK) and
anti-IL-25 or anti-IL17BR antibodies, at increasing con-
centrations. The cultures were kept for 3 days and the cell
supernatants were used to measure IL-13 production by
enzyme-linked immunosorbent assay (ELISA).
ELISA analysis
Flat-bottomed 96-well ELISAmicrotiter plates (MAXISORP;
Nunc, Roskilde, Denmark) were coated with 2 lg/ml of
capture antibodies and held overnight at 4 C. The plates were
washed and blocked for 2 h with phosphate-buffered saline
(PBS)/10 % FBS. For detection, 2 lg/ml of biotinylated
detection antibodies were added for 2 h at room temperature
before washing and incubating were performed with 1 lg/ml
of streptavidin-horseradish peroxidase (SA-HRP), (MP Bio-
medicals, Solon, OH, USA). A peroxidase substrate, 2,20-az-
inobis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma) was
added following the manufacturer’s instructions. The signal
was read spectophotometrically at 405 nm. All antibodies
were purchased from BD Bioscience. These antibodies
included affinity-purified anti-IgE (R35-72), anti-IgG2a
(R19-15), anti-IL-2, anti-IL-4 (11B11), anti-IL-5, anti-IL-10
and anti-IFN-c (XMG1.2). Biotinylated antibodies included
anti-IgE (R35-72), anti-IgG2a (R19-15), anti-IL-2, anti-IL-4,
anti-IL-5, anti-Il-10 and anti-IFN-c. Standard curves were
generated using recombinant mouse cytokines at 1:2 serial
dilutions (R&D Systems). The IL-13 ELISA was performed
using the Quantikine mouse IL-13 Immunoassay from R&D
Systems. To test the specificity of the IL-17BR (clone D9.2)
antibody, plates were coated with 1 lg/ml of IL-17BR-Fc,
IL-17RA, IL-17RC-Fc, IL-17RD (SEF), or a control protein
IL-13Ra-Fc. All proteins were purchased from R&D Systems.
After blocking, anti-IL-17BR (clone D9.2) was used at







0 0 Normal Normal/active
1 1–5 Slightly loose Lack of grooming
2 5–10 Loose stools Piloerection/subdued
3 10–15 Loose stools/blood Splayed legs
4 15–20 Diarrhea/blood Hunched/isolated
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varying concentrations, to test for binding. Detection was
performed using biotinylated anti-mouse IgG1, SA-HRP, and
a peroxidase substrate. The signal was read at 405 nm.
Flow cytometry
All staining procedures were performed in PBS/10 % FBS at
4 C. To block non-specific binding, the single-cell sus-
pensions were incubated with anti-CD16/32 antibodies for
20 min. After washing, the cells were incubated with fluo-
rochrome-conjugated antibodies for 30 min. Stained cells
were analyzed on a FACS Calibur (BD Bioscience). Data
analysis was performed using FlowJo software version 8.8.8
(Tree Star, Ashland, OR, USA). All antibodies used in flow
cytometry were purchased from eBioscience (Hatfield, UK)
and included anti-CD16/32 (clone 93), fluorescein isothio-
cyanate (FITC)-conjugated anti-Gr-1 (clone RB6-8C5),
anti-CD4 phycoerythrin Cy7 (PECy7) (clone GK1.5), phy-
coerythrin (PE)-conjugated CD1d tetramer, anti-Siglec-F
(clone E50-2440), and anti-cd TCR allophycocyanin (APC)
(clone eBioGL3). For the nuocyte staining we used a lineage
combination, with PECy7-conjugated anti-CD3 (clone
145-2C11), CD19 (clone eBio1D3), CD11b (clone M1/70),
Gr1 and B220 (clone RA3-6B2), and inducible T-cell
costimulator (ICOS) conjugated to Alexa fluor 647(clone
C398.4A). For the intracellular staining, cells were previ-
ously stimulated ex vivo with 50 ng/ml phorbol myristate
acetate (PMA) and 500 ng/ml ionomycin for 4 h at 37 C.
All cells also received 1 ll/ml of Golgi plug (BD Biosci-
ence). Following extracellular staining, cells were then fixed,
permeabilized, and stained for IL-13 with anti-IL-13 PE- or
APC-conjugated (eBio13A) according to the manufacturer’s
instructions (BD Biosciences). For the IL-17BR surface
staining, the in-house anti-IL-17BR antibody (clone D9.2)
was conjugated with biotin and used in combination with
streptavidin conjugated to either PECy7 or APCCy7.
Differential white blood cell counts
Blood smears slides were stained with Giemsa (Sigma-
Aldrich), following the manufacturer’s instructions. Dif-
ferential cell counts were made blind on 100 cells per slide
under oil at a 639 magnification.
Quantitative real-time polymerase chain reaction (PCR)
RNA was prepared from lung tissues or from in vitro cultured
primary cells using RNAzolB, according to the manufac-
turer’s instructions (AMS Biotechnology, Oxford, UK). Pre-
designed TaqmanTM primer and probe sets (Applied Biosys-
tems, Carlsbad, California, USA) were used to quantify the
expression of mouse Il25 (Mm00499822_m1). Expression of
Il25 was quantified relative to that of Gapdh (mouse).
Statistical analysis
Results are presented as means ± SEM. The statistical
significance of differences between experimental groups
was analyzed using two-way analysis of variance
(ANOVA) for overall comparisons or the Student’s
unpaired t-test for individual comparisons. P \ 0.05 was
considered as statistically significant. All analyses were
performed using GRAPHPAD PRISM software (GraphPad
Software, La Jolla, CA, USA).
Results
IL-25 expression is increased following oxazolone
instillation
In order to look for the involvement of IL-25 in gut
inflammation we used the oxazolone model of colitis,
known by its clear type-2 immune phenotype [12, 37]. We
used the recently described model of sensitization and
challenge in order to ensure a pronounced colitis with
minimal mortality in the mice [10]. We first analyzed IL-25
production in the gut following oxazolone instillation.
Intestinal epithelial cells (IECs), LP lymphocytes, and the
MLNs were isolated on day two post-challenge to look for
IL-25 expression. IL-25 expression was significantly
increased in IECs derived from colitic mice, and was also
slightly elevated in the MLNs as compared with expression
in the ethanol controls (Fig. 1). No difference in IL-25
expression was seen in the LP lymphocytes isolated from
colitic mice in comparison to those derived from the eth-
anol controls (Fig. 1).
























Fig. 1 Interleukin-25 (IL-25) expression is upregulated during oxa-
zolone colitis. Real-time polymerase chain reaction (PCR) for IL-25
RNA transcripts in intestinal epithelial cells (IECs), lamina propria
(LP) lymphocytes, and mesenteric lymph nodes (MLN). Levels were
normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(n = 5) (**P \ 0.01). EtOH ethanol, OXA oxazolone
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Neutralizing antibodies to IL-25 and IL-17BR improve
the clinical profile of colitis as well as the macroscopic
appearance of colons
In order to test the effects of blocking IL-25 signalling,
administration of anti-IL-25 and anti-Il-17BR neutralizing
antibodies was performed peritoneally 24 h prior to sen-
sitization and challenge with OXA. Isotype control anti-
bodies were administered as appropriate. Oxazolone
challenged IgG1-isotype control treated mice exhibited a
rapid onset of colitis, as early as 24 h post intrarectal
injection, leading to a severe decrease in body weight and
high clinical scores (Table 1). The colitic mice presented
with bloody stools and had lost approximately 15 % of
their weight by day 1 post-injection and around 18 % on
day 2 (Fig. 2a, c). In contrast, weight loss was significantly
reduced in the anti-IL-25- (Fig. 2a) and anti-IL-17BR-
treated mice (Fig. 2c). Treated mice had also recovered
most of their weight loss by day 2, in striking contrast to
colitic animals (OXA?IgG1) that continued losing weight.
Blocking IL-25 or IL-17BR also significantly improved the
clinical phenotype of the mice, with treated mice present-
ing with reduced diarrhea and gross bleeding (Fig. 2b, d;
Table 1). In addition, some of the colitic animals required
euthanasia due to their disease symptoms reaching prede-
termined humane endpoints; this did not occur in anti-IL-
25- and anti-IL-17BR-treated mice. Following these
observations, we sought to look at the phenotypic changes
in the intestine. One of the major macroscopic features of
colitis in mice is the shortening of the colon that occurs due
to ulceration and inflammation [38]. In order to assess the
severity of colitis, we analyzed the macroscopic and
microscopic appearance of the colons on day 2 post-chal-
lenge. We observed a shortening of the colon in the colitic
mice (OXA?IgG1 isotype), which was almost completely
reversed in the anti-IL-25- (Fig. 3a) or anti-IL-17BR
(Fig. 3b) -treated mice. As expected, colons from colitic
mice showed severe bowel edema and hemorrhage
involving the distal 50 % of the colon (Fig. 3). Strikingly,
in mice that received anti-IL-25 and anti-IL-17BR, com-
pared with the untreated animals, the colons appeared to
have less damage to the intestinal walls, less ulceration,
and reduced bloody stools, similar to the findings in the
ethanol controls. H&E staining of colon sections was per-
formed to confirm our observations at a microscopic level.
Colitic (OXA?IgG1) colons showed a disrupted epithelial
cell layer due to extensive ulceration, accompanied by a
reduction of the density of tubular glands and dense infil-
tration of the superficial layers of the mucosal tissue
(Fig. 3c). However, anti-IL-25- or anti-IL-17BR-treated
colons presented with very little inflammation (Fig. 3c). In
summary, blocking IL-25 signalling via neutralizing anti-
bodies against IL-25 or IL-17BR significantly improved the
outcome of the disease and the macroscopic inflammation
in the colon.
Colitis-induced blood eosinophilia and serum IgE
are less pronounced following IL-25 and IL-17BR
neutralization
Type-2 inflammatory responses are characterized by
increased serum IgE and recruitment of eosinophils [39].
Administering IL-25 peritoneally has been shown to induce






























































































Fig. 2 Neutralizing antibodies
to IL-25 or IL-17BR ameliorate
the onset of colitis. Mice were
sensitized and challenged
intrarectally with either
oxazolone (OXA) or ethanol
(EtOH). Anti-IL25 (a, b) or
anti-IL17BR monoclonal
antibodies (mAbs) (c, d) were
given intraperitoneally before
sensitization and challenge. The
clinical onset of disease was
evaluated by the loss of body
weight (a, c) and the clinical
disease index (b, d). Data from




10–20 mice per group. The
values represent means ± SEM
(*P \ 0.05/***P \ 0.001)
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reasons we sought to assess blood eosinophil levels in
colitic mice as well as quantifying serum IgE. Blood and
blood smears were collected on day 2 post-injection. Total
IgE levels were quantified by ELISA and differential cell
counts were performed on blood smears. Circulating IgE
levels were significantly elevated in the OXA?IgG1 colitic
mice in comparison with ethanol controls, but this increase
was significantly reduced in mice administered with anti-
IL-25 (Fig. 4a) or anti-IL-17BR (Fig. 4b). In contrast, the
production of IgG2a, an isotype more typically seen
in type-1 inflammation, remained unchanged in all the











































 + mIgG1 + α−IL-25 + α−IL-17BR
+ Oxazolone+ Oxazolone + Oxazolone
Fig. 3 The macroscopic clinical signs of oxazolone colitis are
reversed by treatment with neutralizing antibodies to IL-25 and IL-
17BR. Analysis was performed on day 2 post-intrarectal injections,
and the length of the colon and its macroscopic appearance were
evaluated. Colon length and macroscopic appearance of colons from
anti-IL-25- (a) and anti-IL-17BR-treated mice (b). Colon sections
from each group were collected for H&E staining (9100) (c). Black
bars represent 100 lm. Data from each antibody represent two
separate experiments (each representative of two independent exper-
iments) with 10 mice per group (****P \ 0.0001)
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anti-IL-17BR treatment resulted in a significant decrease in
the circulating numbers of eosinophils (Fig. 4e, f). Therefore,
blocking IL-25 signalling improved some of the aspects of the
inflammatory response, more specifically reducing plasma
cell release of IgE and eosinophil mobilization.
Blockade of IL-25 signalling down-regulates type-2
cytokines
To investigate the cytokine profile in OXA colitic mice we
isolated MLN cells on day 2 post-challenge and cultured
single-cell suspensions for 48 h in the presence or absence
of anti-CD3/anti-CD28. Cell supernatants were analyzed
by ELISA to quantify cytokine levels. Anti-CD3/CD28
stimulated MLN cells from OXA?IgG1 showed increased
levels of IL-4, IL-5, and IL-13 (Fig. 5a, b). Administration
of anti-IL-25 or anti-IL-17BR reduced the type-2 cytokine
production by MLN cells (Fig. 5). Consistent with the
decrease in serum IgE and eosinophils, IL-4 production
from anti-IL-25- and anti-IL-17BR-treated mice was sub-
stantially reduced (Fig. 5). IL-13 levels were also lower in
the treated mice compared with the isotype control. This
observation was also confirmed in the supernatants of
lamina propria CD45? cells (Fig. 6a, b), and more signif-
icantly so in anti-IL-17BR-treated mice (Fig. 6b). IL-2
production, associated with T-cell proliferation was, per-
haps not surprisingly, increased in the colitic mice. There
was a significant reduction in IL-2 production in cells
derived from anti-cytokine antibody-treated mice. Despite
this, no significant differences between the groups were
seen in the numbers of CD4? or CD8? T cells in the MLN
(data not shown). Some differences were noted in the basal
level of cytokine expression that can be attributed to
experimental variability. No differences in IFN-c or IL-10
production were observed in any of the groups. Therefore,
consistent with our previous observations, blocking IL-25
ameliorates inflammation in the gut by impairing harmful
type-2 cytokine release. These observations are consistent
with a role for IL-25 in regulating the expression of type-2
cytokines [14, 20], but are perhaps more significant for
IL-13, as recent discoveries have shown that IL-25 is
crucial for the induction of IL-13[25, 28].
Impaired IL-25 signalling results in lower innate cell
infiltration in the lamina propria and decreased numbers
of NKT cells in the MLN
Following the observation of increased cell infiltration in
H&E-stained colon sections, we looked at which cell types
were responsible for the cytokine production and the
driving of inflammation in the intestine. In the oxazolone
colitic mice, the colon LP was flooded with inflammatory
cell types, such as CD4? T cells (data not shown), neu-
trophils, cd T cells, eosinophils, NKT cells, and nuocytes
(Fig. 6c). In keeping with our histology study, we observed
almost no cell infiltration in the LP of mice treated with
anti-IL-17BR (Figs. 3c, 6c). We also analyzed the different
cell populations in the MLNs and found that NKT cells
were the only cell type increased in the colitic mice in this
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Fig. 4 Eosinophilia and serum
IgE levels are regulated by
IL-25. IgE levels were measured
by enzyme-linked immunoassay
(ELISA) (a, b) and eosinophils
were counted in slides of blood
smears stained with Giemsa
(c, d). Data are representative of
two experiments (10 mice per
group) (**P \ 0.01)
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did not occur in mice administered with anti-IL-25 or anti-
IL-17BR. No difference between treated and colitic mice
was seen in T-cell numbers or nuocyte numbers in the
MLN (data not shown).
IL-17BR? nuocytes and NKT cells are the cellular
sources of IL-13 in oxazolone colitis
IL-13-producing NKT cells have previously been shown to
drive inflammation in type-2 colitis, both in a mouse model
and in human UC disease [10, 40]. Here we found that
levels of IL-13 were increased in culture supernatants from
MLN cells and LP lymphocytes from colitic mice. To
determine the cellular sources of IL-13 during oxazolone
colitis, we isolated LP and MLN cells on day two post-
challenge and, using intracellular cytokine staining,
examined which cell types expressed IL-13 by flow
cytometry. In the MLN, the numbers of NKT cells
increased following oxazolone instillation (Fig. 6d). In
colitic mice, around 30 % of NKT cells expressed IL-17BR
and 9–10 % of the IL-17BR? NKT cells were also actively
expressing IL-13 (Fig. 7a, b). Both IL-17BR? and IL-
17BR? IL-13? double-positive NKT cells were increased
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Fig. 5 Cytokine production of in vitro unstimulated and anti-CD3/
CD28-stimulated MLN cells. MLN cells were isolated on day 2 post-
challenge and cultured for 48 h in the presence or absence of anti-
CD3 and anti-CD28. Culture supernatants were analyzed by ELISA
for IL-2, IL-4, IL-5, and IL-13 cytokines. Cytokine production by
MLN cells from oxazolone mice treated with anti-IL-25 mAb (a) or
anti-IL-17BR mAb (b). Data are representative of two independent
experiments (n = 6). IFNc interferon c
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(Fig. 7a). No IL-13 expression was detected in cell types
such as CD4? T cells and cd T cells in the MLN, and
although a proportion of CD4? T cells was found to
express IL-17BR, this population was not elevated com-
pared to that in the ethanol controls (data not shown). In the
LP, IL-17BR expression was found in around 40–50 % of
CD4? T cells and NKT cells from colitic mice compared to
20 % in EtOH controls (Fig. 7c). However, IL-13 pro-
duction was not found in either of these cell types (Fig. 7d)
or in cd T cells (data not shown). In the mucosa, we found
that the sole producer of IL-13 on day two following OXA
instillation was the IL-17BR? Lin- ICOS? nuocyte pop-
ulation (Fig. 7e, f). The proportion of IL-17BR/IL-13
double-positive nuocytes was also increased in the colitic
mice compared with that in the ethanol controls (Fig. 7e).
Thus, at the time point analyzed, NKT cells represented the
major source of IL-13 in the MLN, while in the LP, this
role was performed by nuocytes.
Anti-IL-25 and anti-IL-17BR suppress IL-13
production by nuocytes in vitro
Nuocytes have been described recently as the main innate
IL-13-producing cell type that is critical for the develop-
ment of type-2 immune responses in helminth infection and
allergic lung inflammation [28, 41]. In this study we
observed an increase in nuocyte infiltration in the LP of
colitic mice that was inhibited by treatment with anti-IL-
17BR. We also found that nuocytes were the main IL-13-
producing cell type in the LP. Therefore, we sought to
investigate the effect of blocking IL-25 signalling in in
vitro cultures of nuocytes. Nuocytes were cultured in the
presence or absence of IL-25. Cell cultures were also
incubated with anti-IL-17BR or anti-IL-25 for 24–72 h.
We found that anti-IL-17BR antibody inhibited IL-13
production by nuocytes in a dose-dependent fashion
(Fig. 8b) and that this inhibition occurred regardless of
whether the cells were preincubated with the anti-IL-17BR
antibody prior to the addition of IL-25, or whether the
antibody was added at the same time as IL-25 (Fig. 8c). To
discard possible unspecific binding of the antibody we
screened against other IL-17 receptor family members. We
found that anti-IL-17BR was highly specific for the mouse
and human IL-17BR receptors, but showed no cross-reac-
tivity with other IL-17 receptor family members (Fig. 8a).
Anti-IL-25 antibody has been previously shown to have a
therapeutic effect in lung allergy models [23, 25]. Here we
show that, similar to the anti-IL-17BR antibody, anti-IL-25
is also capable of inhibiting IL-13 production from nuo-
cytes in vitro (Fig. 8d).
Discussion
We demonstrate a novel role for IL-25 as a pro-inflam-
















































































Fig. 6 IL-13 production by lamina propria lymphocytes and innate
cell infiltration are reduced in the absence of IL-25. Lamina propria
lymphocytes were isolated on day 2 post-challenge and cultured for
48 h in the presence or absence of anti-CD3 and anti-CD28. Culture
supernatants were analyzed by ELISA for the presence of IL-13 in LP
cells from anti-IL-25-treated (a) or anti-IL-17BR-treated mice (b).
Innate cell infiltration in the lamina propria, as analyzed by flow
cytometry (c) and number of natural killer T (NKT) cells in the
mesenteric lymph node (d). Data are representative of two indepen-
dent experiments (n = 6). Eos eosinophils, nuos nuocytes
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IL-25 prior to the onset of colitis almost completely
reversed the physical symptoms of disease. Administration
of anti-IL-25 or anti-IL-17BR prevented the severe weight
loss typical of colitic mice and significantly improved their
clinical phenotype. This protective effect was shown to be
even more striking upon close analysis of the colons. The
oxazolone model of colitis typically affects the distal half
of the colon [32] and leads to profound changes in the
intestine, including colon shortening due to ulceration [38]
and innate cell and lymphocyte infiltration to the superfi-
cial layer of the mucosa [11]. We found that neutralizing
anti-IL-25 or anti-IL-17BR antibodies protected against
this colon shortening, intestinal bleeding, and disruption of
the mucosal structure. The histology sections showed per-
haps the most obvious difference, with colons from treated
mice presenting with a normal appearance (no changes of
the mucosal wall or cell infiltration).
At a cellular level, we observed intense immune cell
infiltration of the lamina propria (LP) in the colitic mice,
with cells such as neutrophils, eosinophils, and T cells, but
also NKT cells, cd T cells, and, most notably, nuocytes.
This general cell infiltration was not observed when we
a b
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Fig. 7 Nuocytes and NKT cells are the main cellular sources of
IL-13 in oxazolone colitis. Percentages of IL-17BR?/IL-13? and
IL-17BR? NKT cells in the MLN (a). Intracellular IL-13 cytokine
production and surface expression of IL-17BR by NKT cells derived
from the MLN of EtOH or OXA-challenged mice (b). Percentages of
IL-17BR? CD4? T cells and NKT cells in the lamina propria (c);
surface expression of IL-17BR in NKT or CD4? T cells (d).
Percentage of IL-17BR? IL-13? nuocytes in the lamina propria (e).
Intracellular IL-13 cytokine production and surface expression of
IL-17BR in the lineage-ICOS? nuocyte population in EtOH- versus
oxazolone-treated mice (f) (n = 10)
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prevented IL-25 signalling by blocking the IL-17BR
receptor. Moreover, we found a similar trend for the
increase in NKT cells, but not for other cell types, in the
MLN. This increase of the NKT population in both the LP
and MLN has a particular interest, as it correlates with
previous reports in UC patients [40]. Also in oxazolone
colitis, NKT cells have been proposed as the effector cell
type driving type-2-like inflammation. In those studies,
CD1d-deficient mice and invariant NKT (iNKT)-deficient
mice that lacked NKT cells were shown to be protected
from the development of gut inflammation [10]. Studies in
lung allergy also showed that IL-25 could activate a pop-
ulation of IL-17BR? NKT cells which resulted in Th2 cell
activation and eosinophilia [18]. In line with these previous
findings, our data suggest that IL-25 plays a similar role in
the gut by activating IL-17BR? NKT cells to produce
IL-13 and that blocking IL-25 signalling has a profound
positive impact in resolving the intestinal inflammation.
In the case of cd T cells, their specific role in colitis
has not yet been defined. Recent reports have found
contradictory data on the protective or exacerbating role of
cd T cells in the intestinal mucosa, depending on which
colitis model was studied [42]. TCR-a chain-deficient mice
develop a type-2 colitis that is driven by cd T cells [43], but
both cd T cells and ab T cells were found to have accu-
mulated in the inflamed regions of CD and UC patients
[44]. We found here that blocking IL-25 signalling using
anti-IL-17BR decreased the numbers of cd T cells in the
LP, but whether this was due to a direct effect on their
proliferation or to the decreased general level of inflam-
matory cytokines cannot currently be defined. Most inter-
estingly, we also found that the number of lineage-
negative, ICOS? cells (or nuocytes) in the LP was
increased in the colitic mice, as compared to findings in
mice treated with the anti-IL-17BR neutralizing antibody
and the ethanol (EtOH) controls. In addition, we found that,
in the LP, IL-17BR? nuocytes were the sole cellular source
of IL-13 at the time point where inflammation was assessed
and that both anti-IL-25 and anti-IL-17BR blocking anti-
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Fig. 8 Anti-IL-17BR and anti-IL-25 inhibit the production of IL-13
by IL-25-stimulated nuocytes. Anti-IL-17BR antibody was screened
for binding to IL-17 receptor family members and a control protein
IL-13Ra-Fc (a). NBNT cells containing nuocytes were cultured in the
presence of IL-25 and increasing concentrations of anti-IL-17BR, and
IL-13 production was analyzed by ELISA at 72 h (b). NBNT cells
were cultured for 24, 48, and 72 h in the presence of IL-25 and anti-
IL-17BR with and without preincubation with the antibody, and
analyzed for IL-13 production (c). IL-13 production by NBNT cells
cultured for 72 h in the presence of IL-25 and anti-IL25 antibody (d).
Data are representative of two independent experiments. NBNT
nonBnonT cells, O.D. optical density, Sef similar expression to FGF
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Nuocytes have been described recently as a new innate cell
type that is responsive to IL-25 and is the main producer of
IL-13 in the gut during helminth parasite infection [28] and
here we found for the first time the presence of this new
type-2 innate lymphoid cell (ILC) during inflammation in
colitis. Thus, in addition to the NKT cell IL-13 production,
a mechanism of action for IL-25 during type-2 colitic
inflammation can now start to be defined. Intestinal epi-
thelial cells (IECs) are induced to secrete IL-25 by dis-
ruption of the gut microenvironment following oxazolone
instillation. IL-25 then activates IL-17BR? nuocytes in the
LP to produce IL-13 and these events initiate the type-2
inflammatory cascade. It is not surprising to find that IECs
are the main producers of IL-25 in the gut because these
cells form the first barrier of protection against gut patho-
gens. Moreover, this observation is consistent with other
studies, where IL-25 expression was up-regulated in small
intestine epithelial cells, rather than in LP immune cells
following nematode infection [45].
Consistent with a role for IL-25 upstream of type-2
cytokines [10, 11, 37], we found that blocking IL-25 or IL-
17BR had a profound effect on the type-2 cytokine profile,
and that IL-4, IL-5, and IL-13 production was reduced in
the antibody-treated mice. IL-13, IL-4, and IL-5 blocking
strategies have been found to ameliorate oxazolone colitis
[10, 11, 46] and in this study we found that neutralizing IL-
25 produced a similar protective effect. We believe that IL-
25 acts upstream of these type-2 cytokines as an initiating
force of the immune response. In the human disease, IL-13
has been defined as an important cytokine driving the
pathogenesis of UC [40], being expressed by cytotoxic
NKT cells and disrupting the epithelial layer of the colon,
which explains the colonic phenotype of UC [6]. In addi-
tion, more recent studies have again underlined the type-2
phenotype of UC, showing that yet another type-2 initiator
cytokine, IL-33, is involved in the development of
inflammation in the gut [33, 34, 47]. IL-33 has also been
described to play a role in T. muris infection and has been
shown to induce a type-2 cytokine profile in the intestine
[48]. Although we did not find IL-33 expression in this
particular study (data not shown), the fact that IL-25 and
IL-33 lead to similar inflammatory outcomes in the intes-
tine may mean that they are good targets for potential
therapy in UC patients, upstream of the type-2 cytokine
cascade.
IL-25 can have both anti- and pro-inflammatory roles in
the gut, depending on the type of inflammation that is
present. In type-1 responses, such as in DSS and TNBS
colitis, IL-25 clearly plays an anti-inflammatory role
[16, 29]. In previous studies, IL-25 was shown to have a
protective effect towards the development of colitis by
down-regulating IL-12 and IL-23, which, in turn, limits the
Th1-driven inflammatory response. More recently, this
IL-25 protective role has been associated with the activa-
tion of alternatively activated macrophages with anti-
inflammatory properties [30]. Consistent with these find-
ings, chronically infected IL-25-deficient mice develop
severe intestinal inflammation that is Th17-driven [31].
However, none of these studies looked in-depth into specific
type-2-driven intestinal responses, such as the one we used
here. Indeed, in type-2-skewed responses, such as some
parasite infections in the gut, IL-25 clearly drives the
inflammation upstream of IL-4, IL-5, and IL-13 and there-
fore acts as a pro-inflammatory cytokine [27, 28, 31]. These
studies are consistent with our model, where blocking IL-25
signalling using neutralizing antibodies ameliorated the
type-2 inflammation in the gut. Our data add a new key
player in type-2 colitis, showing that IL-25 can act as a
potent pro-inflammatory cytokine in this model.
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